Please login to the form below

Not currently logged in

mantle cell lymphoma

This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma

FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma

BeiGene’s Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been granted a priority review by the US Food and Drug Administration (FDA) for pretreated marginal zone lymphoma (MZL). ... If approved, MZL will become Brukinsa’s second indication

Latest news

More from news
Approximately 5 fully matching, plus 67 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...